High-tech problem for Joe Biden’s COVID vaccine patent waiver

Published May 8, 2021 12:00am ET



The difficulty of learning the technology behind mRNA vaccines poses a major obstacle to President Joe Biden’s proposal aiding poor countries by defying the pharmaceutical industry and waiving patent protections for COVID-19 vaccines.

The rationale for the patent waiver would be to allow developing countries to reproduce currently existing COVID-19 vaccines without having to worry about getting sued by the pharmaceutical companies that hold the patents.

Already a print subscriber? Click here to login/register your account

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.